Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04665115 2022-08-03

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03617484 2020-06-22

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT04043845 2020-02-05

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03232307 2019-08-22

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Lymphoid

Lymphoma, Mantle-Cell

NCT02611908 2019-01-25

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02815059 2018-01-31

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02677948 2017-09-06

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 1/2 Withdrawn

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02950038 2017-02-13

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)